Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 21, 2006; 12(23): 3760-3765
Published online Jun 21, 2006. doi: 10.3748/wjg.v12.i23.3760
Published online Jun 21, 2006. doi: 10.3748/wjg.v12.i23.3760
Table 1 Demographic data of 55 advanced and metastatic small bowel GIST patients treated with or without imatinib meslyate
| Non-Glivec (%) | Imatinib meslyate (%) | P | |
| (n = 33) | (n = 22) | ||
| Age (yr) | 56.5 ± 11.1 | 55.7 ± 15.4 | 0.803 |
| Gender (M : F) | 17 : 16 | 13 : 09 | 0.58 |
| Location | |||
| Duodenum | 4 (12.1) | 5 (22.7) | |
| Jejunum | 22 (66.7) | 8 (36.4) | |
| Ileum | 7 (21.2) | 6 (27.3) | |
| Multiple | 0 (0) | 3 (13.6) | 0.05 |
| Tumor size | |||
| Mean/Median (cm) | 10.3 ± 4.9/9.0 | 11.7 ± 5.1/10.5 | 0.315 |
| Range (cm) | 3.5-25 | 4-24 | |
| Recurrence | 0.022 | ||
| Liver | 28 (84.8) | 11 (50) | |
| Peritoneum | 10 (30.3) | 10 (45.5) | |
| Retroperitoneum | 4 (12.1) | 5 (22.7) | |
| Local | 4 (12.1) | 10 (45.5) | |
| Others | 1 (0.3) | 4 (18.2) |
- Citation: Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate. World J Gastroenterol 2006; 12(23): 3760-3765
- URL: https://www.wjgnet.com/1007-9327/full/v12/i23/3760.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i23.3760